Interim Management Statement

Dechra Pharmaceuticals PLC
24 April 2008

Issued by Citigate Dewe Rogerson Ltd, Birmingham
Date: Thursday, 24 April 2008


                         Dechra(R) Pharmaceuticals PLC
                          Interim Management Statement


Dechra Pharmaceuticals PLC ('Dechra' or the 'Group'), publishes its second
Interim Management Statement as required by the UK Listing Authority Disclosure
and Transparency Rules.

Since the publication of the Group's Half-Yearly Financial Report, trading has
continued in-line with management expectations with both our Pharmaceuticals and
Services Divisions continuing the strong growth seen in the first half of the
financial year.

The financial position of the Group remains healthy.

On 15 January 2008, Dechra completed the acquisition of the entire issued share
capital of VetXX Holdings A/S ('VetXX') for a consideration of £30 million and
DKK 372.4 million (less cash balances of DKK 45.2 million at completion).

The acquisition was financed by a Placing and Open Offer of 11,624,544 New
Ordinary Shares at a price of 303p per share (raising gross proceeds of £35.2
million) and a new bank facility, including refinancing of the Group's existing
facility, totalling £60 million. The integration of VetXX is proceeding to
schedule with the synergy benefits being in-line with management expectations.

The Group's product development programme is making good progress; positive news
is expected on Vetoryl from the US FDA during 2008.

Other than as noted above, there have been no material events or transactions
between 1 January 2008 and the date of this announcement.

The Board remains confident that the Group will continue to make good strategic
progress throughout the remainder of the financial year.



Enquiries:
Ian Page, Chief Executive
Simon Evans, Group Finance Director
Dechra Pharmaceuticals PLC
Tel: [phone]
Mobile: [phone] (IP) or 07775 642220 (SE)
www.dechra.com
[e-mail]

Fiona Tooley, Director
Keith Gabriel, Senior Account Manager
Citigate Dewe Rogerson
Tel: [phone]
Mobile: [phone] (FMT) or 07770 788624 (KG)


Trade Marks appear throughout this release in italics. Dechra and the Dechra 'D'
logo are registered Trade Marks of Dechra Pharmaceuticals PLC.



                      This information is provided by RNS
            The company news service from the London Stock Exchange